Therapeutically, targeting this axis improves EGFR tyrosine kinase inhibitor (TKI) sensitivity: DHHC20 inhibition increases cancer cell dependence on EGFR signaling, sensitizing tumors to TKIs (158). The gene discussed is EGFR; the disease is cancer.